MX2021010122A - Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. - Google Patents

Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.

Info

Publication number
MX2021010122A
MX2021010122A MX2021010122A MX2021010122A MX2021010122A MX 2021010122 A MX2021010122 A MX 2021010122A MX 2021010122 A MX2021010122 A MX 2021010122A MX 2021010122 A MX2021010122 A MX 2021010122A MX 2021010122 A MX2021010122 A MX 2021010122A
Authority
MX
Mexico
Prior art keywords
treatment
neurodegenerative disorders
compound
imidazopyridinyl
compounds
Prior art date
Application number
MX2021010122A
Other languages
English (en)
Inventor
Misoon Kim
Jinhwa Lee
Suyeon Jo
A Yeong Park
Jae Eun Kim
Seung Mook Lim
Keonseung Lim
Original Assignee
1St Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1St Biotherapeutics Inc filed Critical 1St Biotherapeutics Inc
Publication of MX2021010122A publication Critical patent/MX2021010122A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente divulgación proporciona un compuesto de Fórmula (I) o sal farmacéuticamente aceptable, estereoisómeros del mismo, una composición farmacéutica que comprende el compuesto y un método para tratar o prevenir enfermedades neurodegenerativas usando el compuesto. (ver Fórmula).
MX2021010122A 2019-02-22 2020-02-21 Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. MX2021010122A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962809230P 2019-02-22 2019-02-22
PCT/IB2020/051469 WO2020170205A1 (en) 2019-02-22 2020-02-21 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2021010122A true MX2021010122A (es) 2021-09-23

Family

ID=72141573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010122A MX2021010122A (es) 2019-02-22 2020-02-21 Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.

Country Status (10)

Country Link
US (4) US11098044B2 (es)
EP (2) EP3927705A4 (es)
JP (2) JP2022521537A (es)
KR (2) KR20210122862A (es)
CN (2) CN113454081A (es)
AU (1) AU2020224401A1 (es)
CA (1) CA3131059A1 (es)
IL (1) IL285708A (es)
MX (1) MX2021010122A (es)
WO (2) WO2020170205A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098044B2 (en) * 2019-02-22 2021-08-24 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
US20230339978A1 (en) * 2020-08-21 2023-10-26 1ST Biotherapeutics, Inc. Compounds for prevention or treatment of neurodegenerative disorders
CN114599653A (zh) * 2020-09-28 2022-06-07 第一生物治疗股份有限公司 作为造血祖细胞激酶1(hpk1)抑制剂的吲唑及其使用方法
WO2023180976A1 (en) * 2022-03-25 2023-09-28 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same
CN116354959B (zh) * 2023-03-10 2024-04-19 石河子大学 一种N-N桥连噻唑单元的β-咔啉衍生物及其制备方法、应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300359A2 (hu) 2000-02-07 2003-06-28 Abbott Gmbh & Co. Kg. 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
CN101384586A (zh) * 2006-02-14 2009-03-11 诺华公司 Pi-3激酶抑制剂及其应用方法
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
MX2010001824A (es) 2007-08-17 2010-04-21 Icagen Inc Heterociclos como moduladores de canal de potasio.
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
WO2010100144A1 (en) 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
JP6073677B2 (ja) * 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
AR084280A1 (es) * 2010-12-17 2013-05-02 Hoffmann La Roche Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
WO2014004863A2 (en) 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
EP2892534B8 (en) 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG11201504754QA (en) 2012-12-21 2015-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9598424B2 (en) 2014-03-06 2017-03-21 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of TBK1
WO2018017435A1 (en) * 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
WO2018237370A1 (en) * 2017-06-23 2018-12-27 Accro Bioscience Inc. HETEROARYL COMPOUNDS AS INHIBITORS OF THE NECROSIS, COMPOSITION AND METHOD OF USE THEREOF
FI3692023T3 (fi) 2017-10-02 2023-08-17 1St Biotherapeutics Inc Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon
US20230391768A2 (en) * 2018-11-07 2023-12-07 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US11098044B2 (en) * 2019-02-22 2021-08-24 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
US20210347774A1 (en) 2021-11-11
CA3131059A1 (en) 2020-08-27
WO2020170206A1 (en) 2020-08-27
CN113454082A (zh) 2021-09-28
JP2022521536A (ja) 2022-04-08
US11802126B2 (en) 2023-10-31
EP3927705A1 (en) 2021-12-29
CN113454081A (zh) 2021-09-28
US20230365557A1 (en) 2023-11-16
EP3927705A4 (en) 2022-12-07
KR20210122862A (ko) 2021-10-12
EP3927706A1 (en) 2021-12-29
IL285708A (en) 2021-10-31
US11098044B2 (en) 2021-08-24
AU2020224401A1 (en) 2021-10-14
US20220242861A1 (en) 2022-08-04
EP3927706A4 (en) 2022-12-14
KR20210122861A (ko) 2021-10-12
US20200270246A1 (en) 2020-08-27
JP2022521537A (ja) 2022-04-08
WO2020170205A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2021007247A (es) Derivados de rapamicina.
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2020009443A (es) Método de modulación de las vías de señalización de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
MX2021012105A (es) Compuestos de pirrol.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
JOP20210319A1 (ar) مركبات بيروليدين
MX2021007258A (es) Composiciones de esparsentan amorfas.
MX2019004200A (es) Terapia de combinacion.
PH12021550248A1 (en) Borate of azetidine derivative
MX2021014458A (es) Compuestos triciclicos.
EA202193211A1 (ru) Лечение синуклеопатий
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2023002539A (es) Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).